Navigation Links
Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany
Date:6/24/2008

ANTONY, France, June 24 /PRNewswire-FirstCall/ -- Today, Stallergenes has been granted with the marketing authorisation for its sublingual desensitisation tablet, Oralair(R) Grasses in adults, by PEI (Paul Ehrlich Institute), the biological branch of the German health agency.

Based on the positive results of the paediatric pivotal study (VO52), Stallergenes will immediately apply for a paediatric extension of the product's indications.

Stallergenes will launch Oralair(R) Grasses in the adult indication on the German market in the coming weeks. The company expects to extend this launch to the paediatric population this year so as to capture the forthcoming prescription period for grass pollen desensitisation in both indications.

Subsequent market authorization in Europe will be applied afterwards through a Mutual Recognition Procedure (MRP) for both indications, Germany being the reference member state.

"The registration of Oralair(R) Grasses in Germany is a significant breakthrough that gives desensitisation treatments the same level of recognition as mainstream pharmaceuticals and creates a new therapeutic class: "the allergens". I am particularly proud of the fact that Stallergenes has succeeded in turning itself into a genuine biopharmaceutical company, capable of developing and registering pharmaceuticals that meet the highest regulatory standards. We expect the Oralair programme to bring in a steady flow of product licenses in the next few years," says Albert Saporta, Chairman and CEO of Stallergenes.

About The Oralair development programme

According to World Health Organisation (WHO) estimates, 20 to 25% of the world's population suffer from respiratory allergic symptoms, rhinitis and/or asthma. By 2020, 50 % of the world's population will be concerned by allergy according to ISAAC study. According to WHO, desensitisation is the only treatment that addresses the immunological cause of allergy and modifies the natural course of the disease. Nearly 15 to 20% of these patients suffer from moderate to severe allergic rhinitis and rhino-conjunctivitis, not controlled by their usual medical treatment.

Since 2003, Stallergenes has been carrying out the Oralair programme which addresses these unmet medical needs with EBM-documented, registered allergen tablets that are safe and easy-to-use.

This programme consists in the development of the four main allergens accounting for more than 80% of the epidemiology of these allergies: grass pollens, house dust mites, birch pollen and ragweed pollen.

The entire programme is in the clinical development stage and is proceeding according to schedule.

About Oralair(R) Grasses

With a safe and easy-to-use daily dose of Oralair(R) Grasses, patients enjoy a very significant alleviation of all their rhino-conjunctivitis symptoms, a marked reduction in their symptomatic medication use and a noticeable improvement in their quality of life.

Oralair(R) Grasses is a fast-dissolving tablet that has demonstrated high efficacy in allergic rhino-conjunctivitis to grass pollen in the first season, throughout the pollen season and at the pollen peak on:

- poly- and mono-sensitised patients, as well as asthmatic patients,

- every individual symptom, and in peculiar in nasal congestion and

watery eyes

Oralair(R) Grasses is a pre-coseasonal treatment: it has to be started four months before the pollen season, maintained throughout the season, then stopped and restarted the following season.

Oralair(R) Grasses contains a mix of 5 standardised grass allergens: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum), as a daily dose of 300 IR, so as to mimic patients' natural exposure.

The clinical development programme has already enrolled around 1600 patients to date.

A long term pivotal study is proceeding according to schedule, and is currently in its second year.

The company plans to file two INDs for adult and paediatric trials with the FDA this year.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatments, Stallergenes devotes 18% of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and is part of the sample composing the SBF 120 index.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP

Additional information is available on http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
3. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
4. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
8. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. Barr Receives Approval for Generic Combunox(R) Tablets, 5mg/400mg
11. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... According ... activated carbon (PAC)-based materials do not have negative short- or long-term effects on ... contaminated with polychlorinated biphenyls (PCBs) located at the Puget Sound Naval Shipyard & ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... The ... use of health IT to create efficiencies in healthcare information exchange and a statutory ... W. Rucker, MD, head of the federal Office of the National Coordinator for Health ...
(Date:6/23/2017)... WI (PRWEB) , ... June ... ... announce the launch of a redesigned, easier-to-navigate website for all six of ... boards for physicians, nurses, dentists, pharmacists, physical and occupational therapists, and biotechnicians, ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to ... from hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):